



Biogen to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

Cambridge, MA, [Biogen Inc.](#) (Nasdaq: BIIB) announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will participate in a fireside chat during the 42nd Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 8, 2024, at 2:15 p.m. ET. To access the live webcast, please visit the Investors section of Biogen's website at [investors.biogen.com](#). An archived version of the webcast will be available for at least 30 days following the presentation.

About Biogen

Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer's disease, the first treatment to target a genetic form of ALS, the first oral treatment approved for postpartum depression, and the first approved treatment for Friedreich's ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

We routinely post information that may be important to investors on our website at [www.biogen.com](#). Follow us on social media - [Facebook](#), [LinkedIn](#), [X](#), [YouTube](#).

Contact:

Karen Jewell
Investor Relations
Biogen
781.464.2442